KMID : 1036020240130010061
|
|
ÁöÁú.µ¿¸Æ°æÈÇÐȸÁö 2024 Volume.13 No. 1 p.61 ~ p.68
|
|
Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?
|
|
Ramesh Patel
Jai Bharat Sharma Saraswati Rajput
|
|
Abstract
|
|
|
ObjectiveStatins play a key role in the management of atherosclerotic cardiovascular disease for both primary and secondary prevention. However, their increasing usage has correspondingly led to a higher incidence of adverse effects, with muscle symptoms being the most common. An intriguing drug interaction exists between ticagrelor and high-intensity statins, which may exacerbate the adverse effects of statin-induced rhabdomyolysis, leading to significant consequences. This study was conducted to examine the profile of patients who have experienced statin-induced rhabdomyolysis while undergoing percutaneous transluminal coronary angioplasty (PTCA).
MethodsThis was an observational study that included 1,862 patients who underwent PTCA at our institute over the course of 1 year.
ResultsOver a 1-year period, we encountered four patients who were being treated with high-intensity statin therapy following acute coronary syndrome. These patients presented with muscle weakness and kidney injury. A notable commonality among all patients was the co-prescription of ticagrelor. Two patients died, while the other 2 were successfully managed through hydration, electrolyte balance, dialysis, and alternative lipid management drugs.
ConclusionThe concomitant use of ticagrelor and high-intensity statins should be carefully considered due to the additional risk of rhabdomyolysis and kidney injury. Future pharmacokinetic studies are needed to establish a causal relationship and predict potential drug interactions, which, if not avoided, could be fatal.
|
|
KEYWORD
|
|
Statins, Rhabdomyolysis, Drug interactions, Adverse drug reactions, Ticagrelor
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|